ImmuCell Corporation Investor Presentation August 2025 (Nasdaq: ICCC) 2 Table of Contents | 1) | Company Overview and Strategic Opportunity..…….……..…………………………………………………….….… 4-27 | | --- | --- | | 2) | Testimonials………………………………………………………………….……..…….…………………………………….……….…28-32 | | 3) | Financial Review(1).………………..….……..……………………………..……………………………………………..… 33-39 | | 4) | Other Information..……………...………...………………………………………….……………………………...……….…….40-52 | (1)Detailed financial reports, summary press releases and conference ...

Company Overview and Strategy - ImmuCell Corporation focuses on growth in First Defense product line sales and aims to revolutionize subclinical mastitis treatment with Re-Tain[10] - The company addresses the $2 billion annual economic harm to the dairy industry caused by mastitis without traditional antibiotics, using Re-Tain (subject to FDA approval)[10, 53] - Three critical action items include growing First Defense sales, achieving FDA approval for Re-Tain, and proving market acceptance of Re-Tain with $10 million annual production capacity[18] - The company completed an investment to increase First Defense production capacity to over $30 million in annual sales value[29, 49] Product Lines and Market Opportunities - The U S market opportunity for calf-level products to prevent scours is approximately $31 1 million annually[32, 51] - The U S market opportunity for calf-level and dam-level vaccine products used to prevent scours is estimated at $81 8 million annually[32, 51] - Mastitis causes an estimated $2 billion in economic loss to the dairy industry each year[33, 52] Financial Performance - As of March 31, 2025, the company's cash and cash equivalents were $4 6 million, and total assets were $45 6 million[83] - For the three-month period ended March 31, 2025, product sales were $8 1 million, with a gross margin of 42%[87] - The company's total project cost for First Defense is estimated at $14 177 million, and for Re-Tain, it's $5 382 million[90]